Table 1.
Baseline characteristics.
Characteristics | Total population (n=101) | Responders (n=68) | Nonresponders (n=33) | P value |
---|---|---|---|---|
Age (years) | 61.22 ± 9.54 | 61.65 ± 10.39 | 60.33 ± 7.55 | 0.473 |
Sex (female) | 31 (30.7%) | 19 (27.9%) | 12 (36.4%) | 0.389 |
BNP (ng/L) | 401 (213–1185) | 321 (181.3–1129) | 685 (325.5–1230) | 0.537 |
NYHA class | ||||
II | 21 (20.8%) | 15 (22.1%) | 6 (18.2%) | 0.652 |
III | 60 (59.4%) | 40 (58.8%) | 20 (60.6%) | 0.864 |
IV | 20 (19.8%) | 13 (19.1%) | 7 (21.2%) | 0.804 |
HF duration (months) | 48 (12–72) | 30 (12–72) | 60 (30–96) | 0.192 |
Hypertension, n (%) | 21 (20.8%) | 15 (22.1%) | 6 (18.2%) | 0.652 |
CRD, n (%) | 18 (17.8%) | 11 (16.2%) | 7 (21.2%) | 0.535 |
ICM, n (%) | 17 (16.8%) | 12 (17.6%) | 5 (15.2%) | 0.756 |
LVEF (%) | 29.40 ± 4.42 | 29.56 ± 4.10 | 29.08 ± 5.06 | 0.609 |
LAD (mm) | 44.39 ± 5.48 | 43.41 ± 5.20 | 46.43 ± 5.58 | 0.009 |
LVEDD (mm) | 70.06 ± 7.84 | 68.68 ± 7.38 | 72.91 ± 8.12 | 0.010 |
MR (cm2) | 7.2 (4.5–10.4) | 7.2 (4.5–10.4) | 7.5 (4.4–10.4) | 0.278 |
QRS duration (ms) | 165.30 ± 21.33 | 171.20 ± 21.56 | 153.30 ± 15.07 | < 0.001 |
LBBB, n (%) | 62 (61.4%) | 47 (69.1%) | 15 (45.5%) | 0.022 |
Mean follow-up time (months) | 23.76 ± 14.48 | 23.60 ± 14.83 | 24.09 ± 13.95 | 0.875 |
Values are mean ± SD, median (range) or n (%). BNP: brain natriuretic peptide; NYHA: New York Heart Association; HF: heart failure; CRD: chronic renal dysfunction; ICM: ischemic cardiomyopathy; LVEF: left ventricular ejection fraction; LAD: left atrial dimension; LVEDD: left ventricular end-diastolic dimension; MR: mitral regurgitation; LBBB: left bundle branch block.